July 10, 2020July 10, 2020
FDA Accelerated Approval of Melflufen Sought for Hard-to-treat Myeloma Patients
News
Oncopeptides has submitted a new drug application to the U.S. Food and Drug Administration (FDA) requesting the accelerated approval of melflufen ... Read more
July 1, 2020July 1, 2020
1,066 Myeloma Patients Answer HealthTree Survey of COVID-19’s Effects
News
Over some four weeks, 1,066 people with multiple myeloma took part in a survey sponsored by HealthTree to better understand how COVID-19 ... Read more
June 30, 2020June 30, 2020
FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials
News, syndicated
The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly ... Read more
June 29, 2020June 29, 2020
Ninlaro Maintenance Therapy Improves Survival in Patients Not Given ASCT, Trial Shows
News
First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple myeloma who had not been ... Read more
June 26, 2020June 26, 2020
Oncopeptides Reports Positive Results from HORIZON Trial of Melflufen Combo
News
The combination therapy of melflufen (melphalan flufenamide) and dexamethasone continues to be safe and to elicit deep and durable ... Read more
June 24, 2020June 24, 2020
Belantamab Mafodotin Continues to Show Promise in Advanced Myeloma Trials
News
Belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, continues to show promise when used alone or in combination with other approved ... Read more
June 22, 2020June 22, 2020
JNJ-4528 Continues to Show Strong, Durable Responses in Trial
News
Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528, continues to lead to strong and durable responses in ... Read more
June 17, 2020June 17, 2020
Phase 3 Trial of Melflufen Combo in Advanced Multiple Myeloma Fully Enrolled
News
A pivotal Phase 3 study investigating melflufen (melphalan flufenamide) plus dexamethasone in people with relapsed or refractory multiple myeloma is fully ... Read more
June 15, 2020June 15, 2020
UK’s NICE Issues Draft ‘No’ Decision for Sarclisa Triple Combo
News
The U.K.’s National Institute for Health and Care Excellence (NICE) has issued a draft “no” statement on the triple ... Read more
June 12, 2020June 12, 2020
Xpovio Triple Combo Before FDA for Previously Treated Myeloma Patients
News
Karyopharm Therapeutics is asking that Xpovio (selinexor) be approved with Velcade (bortezomib) and low-dose dexamethasone to treat people with multiple ... Read more
June 5, 2020June 5, 2020
New Under-the-skin Darzalex Formulation Approved in EU
News
The European Commission (EC) has approved a new under-the-skin (subcutaneous), fixed-dose formulation of Janssen’s Darzalex (daratumumab) for the treatment ... Read more
June 3, 2020June 3, 2020
Sarclisa Triple Combo Approved in Europe for Advanced Myeloma Patients
News
The European Commission (EC) has approved Sanofi‘s Sarclisa (isatuximab), in a triple combination with Pomalyst (pomalidomide) and dexamethasone, to treat adults with relapsed ... Read more

July 10, 2020July 10, 2020

FDA Accelerated Approval of Melflufen Sought for Hard-to-treat Myeloma Patients

News

Oncopeptides has submitted a new drug application to the U.S. Food and Drug Administration (FDA) requesting the accelerated approval of melflufen (melphalan flufenamide) plus dexamethasone for hard-to-treat patients with multiple myeloma. ... Read more

July 1, 2020July 1, 2020

1,066 Myeloma Patients Answer HealthTree Survey of COVID-19’s Effects

News

Over some four weeks, 1,066 people with multiple myeloma took part in a survey sponsored by HealthTree to better understand how COVID-19 is affecting life for those with this blood cancer. The ... Read more

June 30, 2020June 30, 2020

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

News, syndicated

The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported symptoms from cancer trials for ... Read more

June 29, 2020June 29, 2020

Ninlaro Maintenance Therapy Improves Survival in Patients Not Given ASCT, Trial Shows

News

First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple myeloma who had not been initially treated with an autologous stem cell transplant (ASCT), according ... Read more

June 26, 2020June 26, 2020

Oncopeptides Reports Positive Results from HORIZON Trial of Melflufen Combo

News

The combination therapy of melflufen (melphalan flufenamide) and dexamethasone continues to be safe and to elicit deep and durable responses in hard-to-treat patients with relapsed or refractory multiple myeloma, ... Read more

June 24, 2020June 24, 2020

Belantamab Mafodotin Continues to Show Promise in Advanced Myeloma Trials

News

Belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, continues to show promise when used alone or in combination with other approved therapies to treat people with relapsed or refractory multiple myeloma, ... Read more

June 22, 2020June 22, 2020

JNJ-4528 Continues to Show Strong, Durable Responses in Trial

News

Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528, continues to lead to strong and durable responses in all patients with relapsed or refractory disease who are participating ... Read more

June 17, 2020June 17, 2020

Phase 3 Trial of Melflufen Combo in Advanced Multiple Myeloma Fully Enrolled

News

A pivotal Phase 3 study investigating melflufen (melphalan flufenamide) plus dexamethasone in people with relapsed or refractory multiple myeloma is fully enrolled, Oncopeptides, the treatment’s developer, announced. The OCEAN trial (NCT03151811) ... Read more

June 15, 2020June 15, 2020

UK’s NICE Issues Draft ‘No’ Decision for Sarclisa Triple Combo

News

The U.K.’s National Institute for Health and Care Excellence (NICE) has issued a draft “no” statement on the triple combination of Sarclisa (isatuximab), Pomalyst (pomalidomide) and dexamethasone as a treatment for people with relapsed ... Read more

June 12, 2020June 12, 2020

Xpovio Triple Combo Before FDA for Previously Treated Myeloma Patients

News

Karyopharm Therapeutics is asking that Xpovio (selinexor) be approved with Velcade (bortezomib) and low-dose dexamethasone to treat people with multiple myeloma after at least one line of therapy. The request ... Read more